Today, May 19, 2025, is the day the allotment for the Accretion Pharmaceuticals IPO is expected to be finalized. This highly anticipated IPO, which closed for subscription on May 16, 2025, saw an enthusiastic response from investors, being oversubscribed by nearly 7.6 times. The IPO aimed to raise ₹29.75 crores through a fresh issue of 29,46,000 shares.

Checking Your Allotment Status Online: A Step-by-Step Guide

Investors can check their allotment status through two primary channels: the registrar's website and the NSE SME platform.

1. Via the Registrar (KFin Technologies Limited):

• Visit the KFin Technologies Limited website, the registrar for the Accretion Pharmaceuticals IPO.
• Look for the "IPO Allotment Status" option on the homepage.
• You will need to enter either your PAN, application number, or Demat account number.
• Click the "Submit" button to view your allotment status.

2. Via the NSE SME Platform:

• Go to the official website of the National Stock Exchange Small and Medium Enterprises (NSE SME).
• You will need your application number and PAN to check the status.

Understanding the Allotment Structure

Accretion Pharmaceuticals had reserved specific quotas for different investor categories: 50% for Qualified Institutional Buyers (QIB), 15% for Non-Institutional Investors (NII), and 35% for Retail Individual Investors (RII), in accordance with SEBI regulations. A smaller portion, 7.17%, was allocated to Anchor Investors.

Grey Market Premium (GMP) and Listing

As of today, May 19, 2025, the grey market premium (GMP) for Accretion Pharmaceuticals IPO is reportedly flat, with unlisted shares trading around ₹101 apiece. This suggests a potential flat listing for the company's shares. However, it's crucial to remember that GMP is dynamic and can change due to various market factors.

The shares of Accretion Pharmaceuticals are tentatively scheduled to be listed on the NSE SME platform on Wednesday, May 21, 2025.

About Accretion Pharmaceuticals

Accretion Pharmaceuticals, established in 2012, is a pharmaceutical company involved in manufacturing and marketing tablets, capsules, oral liquids, and external preparations. They also offer contract and loan license manufacturing services. The company has a presence in over 20 countries across Africa, Southeast Asia, and the Middle East. Their manufacturing facility is located in Sanand, Ahmedabad, and holds ISO certifications.

Financial Performance and IPO Objectives

Accretion Pharmaceuticals aims to utilize the funds raised through the IPO for capital expenditure towards machinery and equipment, repayment or prepayment of borrowings, working capital requirements, and general corporate purposes.

The company's financial performance shows a positive trajectory. Revenue increased from ₹2,938.43 lakhs in March 2023 to ₹3,366.52 lakhs in March 2024. Profit after tax (PAT) also saw a significant increase from ₹10.39 lakhs in March 2023 to ₹387.53 lakhs in March 2024. The diluted EPS increased from ₹0.26 in March 2023 to ₹9.69 in March 2024, reflecting higher earnings per share for investors.